You are here

Article Text

Article menu
Download PDFPDF
Commentary
General medicine
Erenumab is effective in reducing migraine frequency and improving physical functioning
  1. Paolo Martelletti
  1. Universita degli Studi di Roma La Sapienza Dipartimento di Medicina Clinica, Roma, Italy
  1. Correspondence to Prof. Paolo Martelletti, Universita degli Studi di Roma La Sapienza; Paolo.Martelletti{at}uniroma1.it

https://doi.org/10.1136/bmjebm-2018-110937

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Goadsby PJ, Reuter U, Hallström YA, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017;377:2123-2132.

     Context

    Migraine presents an important social, economic and disability burden in 14% of affected population.1 The age range more compromised is under 50, which represents a burden in personal, social and working functioning.1

    Migraine treatments are old and with low compliance by the patient for adverse events. Erenumab is a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor (CGRPr) showing promising evidences from a controlled trial in episodic migraine.2

    Methods

    This randomised, double-blind, multicentre, placebo-controlled trial of erenumab in episodic migraine has been carried out through the monthly subcutaneous administration of either erenumab or placebo for a 6-month period. In total, …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Patient consent Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.